Hongjin Liang

Hongjin Liang

Auto-generated profile, based on publicly available information

Hongjin Liang

Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, CHN

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2019 in FEBS Letters
Verified
Journal Article
Open access
PDF file
HLHongjin Liang
Hongjin Liang
XXXina Xie
Xina Xie
XSXuhong Song
Xuhong Song
MHMeihui Huang
Meihui Huang
TSTing Su
Ting Su
DHDongyang Huang
Dongyang Huang
Homocysteine (Hcy) is associated with nonalcoholic fatty liver disease (NAFLD). orphan nuclear receptor subfamily 4 group A member 1 (NR4A1) is involved in hepatic lipid metabolism. However, the potential role of NR4A1 in Hcy‐associated NAFLD remains elusive. We aimed to elucidate the regulation of NR4A1 and its significance in Hcy‐induced NAFLD. Hcy induced steatosis and elevated the expression of CD36 and FATP2 in HepG2 cells. Furthermore, Hcy enhanced p300 and decreased HDAC7 recruitment to the NR4A1 promoter, resulting in histone H3K27 hyperacetylation and NR4A1 upregulation. Moreover, NR4A1 depletion not only mimicked but also exaggerated the effects of Hcy on steatosis, whereas NR4A1 agonist Cytosporone B (CsnB) blocked Hcy‐induced steatosis. In hyperhomocysteinemia (HHcy) mice, CsnB attenuated HHcy‐induced hepatic steatosis. Thus, Hcy transiently and rapidly induces NR4A1 expression to reduce Hcy‐induced steatosis.

16 June 2013 in ACM SIGPLAN Notices
Verified
Journal Article
Open access
PDF file
HLHongjin Liang
Hongjin Liang
XFXinyu Feng
Xinyu Feng
Locating linearization points (LPs) is an intuitive approach for proving linearizability, but it is difficult to apply the idea in Hoare-style logic for formal program verification, especially for verifying algorithms whose LPs cannot be statically located in the code. In this paper, we propose a program logic with a lightweight instrumentation mechanism which can verify algorithms with non-fixed LPs, including the most challenging ones that use the helping mechanism to achieve lock-freedom (as in HSY elimination-based stack), or have LPs depending on unpredictable future executions (as in the lazy set algorithm), or involve both features. We also develop a thread-local simulation as the meta-theory of our logic, and show it implies contextual refinement, which is equivalent to linearizability. Using our logic we have successfully verified various classic algorithms, some of which are used in the java.util.concurrent package.

30 July 2023 in Cureus
Verified
Journal Article
Open access
PDF file
HLHong-Jin Liang
Hong-Jin Liang
XJXiao-Min Jiang
Xiao-Min Jiang
FSFeng-Cai Shen
Feng-Cai Shen
JPJian-Hua Peng
Jian-Hua Peng
DWDan-Min Wang
Dan-Min Wang
LLLing Lin
Ling Lin
Background: Studies investigating the association between single nucleotide polymorphisms (SNPs) of tumor necrosis factor-alpha (TNFα) and the efficacy of adalimumab (ADA) in ankylosing spondylitis (AS) therapy have reported conflicting results. We aimed to investigate the value of SNP typing of TNFα in predicting the efficacy of ADA in AS. Materials and methods: Eighty patients with active AS who received ADA treatment were followed up for 24 weeks. Six known SNPs of TNFα (+489G/A, -238G/A, -308G/A, -857C/T, -863C/A, and -1031C/T) were subjected to the SNaPshot SNP typing method, which has been proven to be a reliable, efficient, and cost-effective method for detecting SNPs. The relationship between each SNP genotype and the therapeutic efficacy of ADA was analyzed. Results: At the end of the 24-week follow-up, 58.8% of the patients with AS achieved Assessment of SpondyloArthritis International Society (ASAS) partial remission (PR), 67.5% of the patients achieved the criteria of an ASAS40 response (40% improvement on indices), and 53.8% of the patients achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement (MI). The univariate analysis showed that patients with AS carrying the TNFα +489 A allele were more likely to achieve ASAS-PR, ASAS40 response criteria, and ASDAS-MI after ADA treatment. In the multivariate regression analysis, the TNFα +489 A allele was an independent factor influencing the efficacy of ADA in treating AS (ASAS-PR odds ratio (OR) = 2.66, 95% confidence interval (CI) = 1.01-7.01; ASAS40 OR = 4.56, 95% CI = 1.39-15.00; ASDAS-MI OR = 3.31, 95% CI = 1.02-10.69). Conclusions: The patients carrying the TNFα +489 A allele may be more likely to experience better therapeutic efficacy and achieve the treatment target (ASAS-PR, ASAS40 response, or ASDAS-MI) after receiving ADA treatment. Detection of TNFα +489 G/A may predict the therapeutic efficacy of ADA, which can be used in clinical practice to tailor treatment for individual patients with AS. Further studies with larger sample sizes and longer follow-up periods with imaging evaluation are needed to verify our findings.